A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma

Xiaoting Wei(Peking University), Lu Si(Peking University), Xiaobiao Ma(Huazhong University of Science and Technology), Hongqi Tian(Eli Lilly (United States)), Zhengyun Zou(Nanjing University of Chinese Medicine), Meiyu Fang(Zhejiang Cancer Hospital), Ying Cheng(Jilin Province Tumor Hospital), Zhiguo Luo(Fudan University Shanghai Cancer Center), Yu Chen(Fujian Medical University), Zhongwei Jia(Peking University), Xinlan Liu(Yunnan Agricultural University), Peng Zhang(Chinese Academy of Sciences), Jing Chen(Hebei University of Economics and Business), Xiubao Ren(Tianjin Medical University Cancer Institute and Hospital), Junping Zhang(Tianjin University of Traditional Chinese Medicine), Gang Huang(Shanghai Jiao Tong University), Jiwei Liu(Northeast Normal University), Jiyan Liu(Zhejiang University), Hongming Pan, Jun Guo(Peking University), Xiaoshi Zhang(Sun Yat-sen University), Weizhen Zhang(University of Michigan–Ann Arbor), Di Wu(Foshan University), Renbing Jiang(Xinjiang Medical University)
European Journal of Cancer
March 11, 2024
Cited by 30


Related Papers